Skip to main content

Table 1 Baseline characteristics

From: The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies

Number of patients

401

Age, years

59 (SE 0.6)

Female

76%

Disease duration, years

12 (SE 0.5)

DAS28-ESR at baseline

6.0 (SE 0.1)

RF-positive

81%

Anti-CCP-positive

81%

No previous biologicals

3%

One previous biological

47%

Two previous biologicals

34%

More than two previous biologicals

15%

  1. Anti-CCP, anti-cyclic citrullinated peptide antibody; DAS28, disease activity score using 28 joint counts; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; SE, standard error.